Takeda Pharmaceuticals Partners with Wipro
News May 23, 2014
Wipro Ltd. has announced a strategic partnership with Takeda Pharmaceutical Company Ltd., the largest pharmaceutical company in Japan and one of the global leaders of the industry.
This strategic partnership will build advanced value in Takeda's operations by consolidating IT platforms across the organization. As a strategic partner, Wipro will build and maintain an "as-a-service" global platform for Takeda that will drive synergies across its global entities through standardization of IT architecture.
Wipro will be primary provider of IT Infrastructure management services covering Takeda's entities across the world, touching 30,000 users in 16 different languages, operating out of data centers in Asia, Europe and America.
Speaking on the engagement, Sangita Singh, Chief Executive - Healthcare and Life Science Business Unit at Wipro said, "We are thrilled to partner with Takeda in its business transformation journey. Wipro is leveraging its experience in enabling global pharma companies to achieve a leaner & standardized IT workplace and implement newer business models that put patient at the core. We look forward to collaboratively partnering with the Takeda team in enabling this unique platform across its global operations."
"Wipro will deliver the "as-a-service" on demand model, which is redefining the way organizations purchase technology. With our global delivery capabilities, Wipro will drive Takeda's IT infrastructure, consolidating and optimizing resources across the organization," added G K Prasanna, Chief Executive - Global Infrastructure Services & Product Engineering Services.
PhoreMost and Plexxikon Collaborate to Identify Novel Drug TargetsNews
PhoreMost, the UK-based biopharmaceutical company dedicated to drugging ‘undruggable’ disease targets, today announced it has signed a collaborative agreement with Plexxikon Inc., the small molecule structure-guided R&D centre of Daiichi Sankyo.READ MORE
Lonza Opens World’s Largest Dedicated Cell-and-Gene-Therapy Manufacturing Facility in TexasNews
First-of-its-kind, state-of-the-art manufacturing facility with capacity to produce treatment for thousands of patients suffering from rare genetic disorders or life-threatening diseases.READ MORE
IONTAS and IGEM Therapeutics Collaborate to Identify Novel IgE AntibodiesNews
The project will add to IGEM’s pipeline of drugs and expand upon IGEM-F, an IgE targeting ovarian and other cancers, currently in a Phase 1/2a study.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018